Merck today announced details [link] about the new phase 2/3 (200 then 1700 patients) clinical trial in mild-to-moderate Alzheimer’s Disease testing the BACE inhibitor MK-8931. This trial will be yet another test of the “amyloid hypothesis” for AD – investors, patients, and researchers will be hoping it goes better than recent trials from Eli Lilly's $LLY solanezumab, and bapineuzumab from Pfizer $PFE – Johnson & Johnson $JNJ – Elan $ELN.
You can find more details on the program in my highlights from a recent Merck R&D day event [link]. Recall that this program is licensed from Ligand Pharma $LGND (well, it arose two mergers ago in a drug discovery deal between Schering Plough $SGP and Pharmacopeia $PCOP). Check the archive of LGND-related posts to see what MRK has said about the program at other events and webcasts.
Continue reading for the complete info and data from four abstracts about the drug presented at the AAIC meeting earlier in 2012.
You can find more details on the program in my highlights from a recent Merck R&D day event [link]. Recall that this program is licensed from Ligand Pharma $LGND (well, it arose two mergers ago in a drug discovery deal between Schering Plough $SGP and Pharmacopeia $PCOP). Check the archive of LGND-related posts to see what MRK has said about the program at other events and webcasts.
Continue reading for the complete info and data from four abstracts about the drug presented at the AAIC meeting earlier in 2012.
RSS Feed
